Recent reports from the United Nations and RAND Corporation highlight the growing interest and potential risks associated with the use of psychedelics like Ketamine and LSD. The UN warns that investors are outpacing scientific research, potentially endangering users' health. RAND Corporation urges federal policymakers to decide on regulating psychedelics to avoid a fragmented state-by-state approach.
As Restrictions on Cannabis and Psychedelics Ease, Americans Dabble with ‘Microdosing’ https://t.co/aiXBaLKimp #news #biotech
Don't be surprised if the FDA approves MDMA despite its' advisers objections; a decades-long campaign by advocates has turned agency officials into enthusiastic supporters of psychedelic research, explains @OliviaGoldhill https://t.co/ee6hSHaRgX via @statnews
UN Annual Drug Report Says Marijuana Legalization May Shrink Illicit Market And Notes Emergence Of 'Psychedelic Renaissance' https://t.co/YQx0RRN775
.@RANDCorporation: "Now is the time" for feds to decide how to regulate psychedelics "Or if they prefer a patchwork of state policies—possibly including those that allow for commercial supply & promotion—they can do nothing & just watch the industry grow" https://t.co/lDH7DteAom
Investors funding a “psychedelic renaissance” are outpacing scientific research into substances like Ketamine and LSD, putting potential drug users’ health at risk, the United Nations warned. https://t.co/FFDANhEZZ9 via @business
🚨 New research 🚨 Now is the time for federal policymakers to decide whether they want #psychedelics to follow in the footsteps of the for-profit cannabis model Our @RANDCorporation report hopes to inform policy debates at federal/state/local levels 🧵 https://t.co/lK9MkUm3WH